Previous 10 | Next 10 |
Several biotechs involved in gene editing are higher on Wednesday in the aftermath of Roche's ( OTCQX:RHHBY ) blockbuster deal with CAR-T-focused Poseida Therapeutics ( PSTX ) announced earlier today. One of the biggest gainers -- up more than 30% -- is Alaunos The...
Adaptimmune ( NASDAQ: ADAP ) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is -$0.29 (-625.0% Y/Y) and the consensus Revenue Estimate is $8.7M (+180.6% Y/Y). Over the last 3 months, EPS estimates ha...
Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - July 21, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the second quarter ended June 30, 2022, before th...
Baillie Gifford’s 13F portfolio value decreased from ~$182B to ~$143B this quarter. They increased Affirm Holdings, Coupang, and Ginkgo Bioworks while reducing Petroleo Brasileiro and First Republic Bank. The top three positions are Tesla Motors, Moderna, and Illumina, and ...
There are some incredible deals in biotech right now. Three Fool.com contributors think Adaptimmune Therapeutics (NASDAQ: ADAP) , G1 Therapeutics (NASDAQ: GTHX) , and Axsome Therapeutics (NASDAQ: AXSM) are on the verge of a big move over the next couple of years. ...
SPEARHEAD-1 trial using afami-cel for the treatment of patients with synovial sarcoma and MRCLS met its primary endpoint with an objective response rate of 34%. A BLA filing for afami-cel for the treatment of patients with synovial sarcoma and MRCLS is expected in Q4 of 2022. The ...
Shares of the British cell therapy company Adaptimmune Therapeutics (NASDAQ: ADAP) are having one of their best days in several months today. Specifically, the biotech's stock is currently up by a respectable 7.72% as of 2:05 p.m. ET Monday. To put this move into the proper cont...
Adaptimmune Therapeutics is a cell therapy company using their TCR-engineered T cells to take on various tumor types. Their leading program is MAGE-A4 which contains afami-cel, a TCR-engineered T cell that targets the MAGE-A4 CTA and is being tried in multiple tumors types. Adapti...
Gainers: Turning Point Therapeutics (TPTX) +117%. Energy Focus (EFOI) +40%. Galecto (GLTO) +25%. Adaptimmune (ADAP) +22%. Amylyx Pharmaceuticals (AMLX) +22%. AudioEye (AEYE) +20%. Sprague Resources LP (SRLP) +20%. Global Cord Blood (CO) +18%. GreenBox (GBOX) +17%. Kopin (KOPN) +15%. Losers: N...
- Patients who responded to afami-cel had longer progression-free survival (median 58 weeks) compared to non-responders (median 12 weeks) - - Responses occurred across subgroups, with greater response rates associated with lower baseline tumor burden, fewer prior lines of therapy, and higher ...
News, Short Squeeze, Breakout and More Instantly...
Adaptimmune Therapeutics plc Company Name:
ADAP Stock Symbol:
NASDAQ Market:
Adaptimmune Therapeutics plc Website:
Approved for advanced MAGE-A4+synovial sarcoma in adults with certain HLA types who have received prior chemotherapy TECELRA is the first new treatment option for people with synovial sarcoma in more than a decade Adaptimmune to hold webcast at https://www.gowebcasti...
2024-07-30 07:30:03 ET H.C. Wainwright analyst issues BUY recommendation for ADAP on July 30, 2024 06:07AM ET. ADAP was trading at $1.37 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 4 - Buy, 1 - Hold, ...
2024-07-30 07:00:10 ET Arthur He from H.C. Wainwright issued a price target of $4.00 for ADAP on 2024-07-30 06:07:00. The adjusted price target was set to $4.00. At the time of the announcement, ADAP was trading at $1.37. The overall price target consensus is at $2.54 wi...